News

Filter

Current filters:

CSL Limited

1 to 9 of 123 results

CSL Behring files BLA for hemophilia B agent

CSL Behring files BLA for hemophilia B agent

18-12-2014

USA-based CSL Behring, a unit of Australia’s CSL Ltd, has submitted a biologics license application…

CSL BehringCSL LimitedHematologyPharmaceuticalRegulationUSA

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Aslan Pharma signs agreement with CSL to develop novel therapy for asthma

19-05-2014

Singapore-based Aslan Pharmaceuticals has signed a global license agreement to develop an anti-interleukin…

ASLAN PharmaceuticalsBiotechnologyCSL LimitedCSL334LicensingRespiratory and Pulmonary

CSL opens Australian biotechnology manufacturing facility

09-05-2014

Leading Australian biotech firm CSL Limited has opened the CSL Behring Biotechnology manufacturing facility…

AustraliaBiotechnologyCSL BehringCSL LimitedHematologyProductionResearch

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Report: IPOs and government support can boost the Australian life sciences industry

Report: IPOs and government support can boost the Australian life sciences industry

18-02-2014

Despite a relatively flat December quarter for the PricewaterhouseCoopers Life Sciences Index, it was…

AustraliaBiotechnologyCSL LimitedFinancialMarkets & MarketingPharmaceutical

Australia’s CSL posts solid half-year results

Australia’s CSL posts solid half-year results

13-02-2014

Australian blood products and vaccine maker CSL reported a 3% rise in net profit to $646 million (all…

CSL LimitedFinancialHematologyPharmaceuticalVaccines

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

08-12-2013

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the…

BayerCardio-vascularCSL BehringCSL LimitedEuropeHelixateHematologyKogenatePharmaceuticalRegulation

1 to 9 of 123 results

Back to top